10-Q
falseQ20001717115--12-31ILRepresents the adoption of a Rule 10b5-1 trading plan by each of Blue Media, LLC and Gray Media, LLC, each an entity controlled by Mr. Lefkofsky, providing for the sale of up to 1,600,000 shares of Class A common stock held by Blue Media, LLC and up to 400,000 shares of Class A common stock held by Gray Media, LLC.Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.This Rule 10b5-1 trading plan provides for sales of up to approximately 94.8% (calculated on a weighted-average basis) of the net number of shares received upon vesting of an aggregate of 158,418 RSUs, after giving effect to the withholding or sale of a portion of such shares to satisfy tax withholding obligations. Accordingly, the aggregate maximum number of shares that may be sold pursuant to this trading arrangement is dependent on the amount of tax withholding required upon the vesting of RSUs, and, therefore, is indeterminable at this time.This Rule 10b5-1 trading plan provides for sales of up to 100% of the net number of shares received upon vesting of an aggregate of 176,447 RSUs with respect to Mr. Polovin, 161,972 RSUs with respect to Mr. Rogers and 35,013 RSUs with respect to Mr. Bartolucci, after giving effect to the withholding or sale of a portion of such shares to satisfy tax withholding obligations. Accordingly, the aggregate maximum number of shares that may be sold pursuant to this trading arrangement is dependent on the amount of tax withholding required upon the vesting of RSUs, and, therefore, is indeterminable at this time. 0001717115 2024-01-01 2024-06-30 0001717115 2023-12-31 0001717115 2024-06-30 0001717115 2024-04-01 2024-06-30 0001717115 2023-04-01 2023-06-30 0001717115 2023-01-01 2023-06-30 0001717115 2023-06-30 0001717115 2024-06-17 2024-06-17 0001717115 2022-12-31 0001717115 2024-03-31 0001717115 2023-03-31 0001717115 us-gaap:NonvotingCommonStockMember 2023-12-31 0001717115 us-gaap:CommonClassBMember 2023-12-31 0001717115 us-gaap:CommonClassAMember 2023-12-31 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember 2023-12-31 0001717115 srt:MinimumMember tem:PathosMember 2023-12-31 0001717115 us-gaap:RelatedPartyMember 2023-12-31 0001717115 tem:PathosMember 2023-12-31 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember 2023-12-31 0001717115 us-gaap:FairValueInputsLevel1Member 2023-12-31 0001717115 us-gaap:FairValueInputsLevel2Member 2023-12-31 0001717115 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001717115 tem:TwoThousandAndFifteenStockOptionPlanMember 2023-12-31 0001717115 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-12-31 0001717115 us-gaap:AccountsReceivableMember 2023-12-31 0001717115 tem:SeriesDMember 2023-12-31 0001717115 tem:SeriesCMember 2023-12-31 0001717115 tem:SeriesB2Member 2023-12-31 0001717115 tem:SeriesB1Member 2023-12-31 0001717115 us-gaap:SeriesBMember 2023-12-31 0001717115 us-gaap:SeriesAMember 2023-12-31 0001717115 tem:SeriesG4Member 2023-12-31 0001717115 tem:SeriesG3Member 2023-12-31 0001717115 tem:SeriesG2Member 2023-12-31 0001717115 tem:SeriesGMember 2023-12-31 0001717115 tem:SeriesFMember 2023-12-31 0001717115 tem:SeriesEMember 2023-12-31 0001717115 us-gaap:TradeNamesMember 2023-12-31 0001717115 us-gaap:CustomerRelationshipsMember 2023-12-31 0001717115 tem:LicensedDataMember 2023-12-31 0001717115 us-gaap:IPOMember 2023-12-31 0001717115 us-gaap:InternetDomainNamesMember 2023-12-31 0001717115 tem:CommercializationAndReferenceLaboratoryAgreementMemberWithPersonalisIncMember tem:PersonalisIncMember 2023-12-31 0001717115 tem:WarrantContractAssetLessCurrentPortionMember 2023-12-31 0001717115 us-gaap:NonvotingCommonStockMember 2024-06-30 0001717115 us-gaap:CommonClassBMember 2024-06-30 0001717115 us-gaap:CommonClassAMember 2024-06-30 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember 2024-06-30 0001717115 us-gaap:RelatedPartyMember 2024-06-30 0001717115 srt:MinimumMember tem:PathosMember 2024-06-30 0001717115 tem:PathosMember 2024-06-30 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember 2024-06-30 0001717115 us-gaap:FairValueInputsLevel1Member 2024-06-30 0001717115 us-gaap:FairValueInputsLevel2Member 2024-06-30 0001717115 us-gaap:FairValueInputsLevel3Member 2024-06-30 0001717115 tem:TwoThousandAndTwentyFourEquityIncentivePlanMember us-gaap:CommonClassAMember 2024-06-30 0001717115 tem:IncentiveStockOptionsMember tem:TwoThousandAndTwentyFourEquityIncentivePlanMember 2024-06-30 0001717115 tem:TwoThousandAndTwentyFourEquityIncentivePlanMember tem:ClassAAndClassBCommonStockMember 2024-06-30 0001717115 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2024-06-30 0001717115 us-gaap:LongTermContractWithCustomerMember 2024-06-30 0001717115 tem:OneYearMember us-gaap:LongTermContractWithCustomerMember 2024-06-30 0001717115 tem:TwoYearMember us-gaap:LongTermContractWithCustomerMember 2024-06-30 0001717115 tem:ThreeYearMember us-gaap:LongTermContractWithCustomerMember 2024-06-30 0001717115 tem:FourYearMember us-gaap:LongTermContractWithCustomerMember 2024-06-30 0001717115 us-gaap:AccountsReceivableMember 2024-06-30 0001717115 tem:CommercializationAndReferenceLaboratoryAgreementMemberWithPersonalisIncMember tem:PersonalisIncMember 2024-06-30 0001717115 us-gaap:CommonClassAMember tem:MasterServicesAgreementWithAstraZenecaAsAmendedMember 2024-06-30 0001717115 us-gaap:TradeNamesMember 2024-06-30 0001717115 us-gaap:CustomerRelationshipsMember 2024-06-30 0001717115 tem:LicensedDataMember 2024-06-30 0001717115 tem:ContingentConsiderationMember 2024-06-30 0001717115 srt:WeightedAverageMember 2024-06-30 0001717115 srt:MaximumMember 2024-06-30 0001717115 srt:MinimumMember 2024-06-30 0001717115 us-gaap:RestrictedStockUnitsRSUMember tem:TwoThousandAndFifteenStockOptionPlanMember 2024-06-30 0001717115 us-gaap:InternetDomainNamesMember 2024-06-30 0001717115 tem:WarrantContractAssetLessCurrentPortionMember 2024-06-30 0001717115 us-gaap:MeasurementInputExpectedTermMember 2024-06-30 0001717115 us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-06-30 0001717115 us-gaap:MeasurementInputPriceVolatilityMember 2024-06-30 0001717115 us-gaap:MeasurementInputExpectedDividendRateMember 2024-06-30 0001717115 us-gaap:AccruedLiabilitiesMember tem:SeriesGFiveRedeemableConvertiblePreferredStockMember 2024-06-30 0001717115 tem:CommercializationAndReferenceLaboratoryAgreementMember tem:PersonalisIncMember 2024-06-30 0001717115 tem:CommercializationAndReferenceLaboratoryAgreementMember tem:PriorDecember312025Member tem:PersonalisIncMember 2024-06-30 0001717115 tem:CommercializationAndReferenceLaboratoryAgreementMember tem:PriorDecember312024Member tem:PersonalisIncMember 2024-06-30 0001717115 tem:ErikPhelpsMember 2024-06-30 0001717115 tem:AndrewPolovinMember 2024-06-30 0001717115 tem:JamesRogersMember 2024-06-30 0001717115 tem:RyanBartolucciMember 2024-06-30 0001717115 tem:EricLefkofskyMember 2024-06-30 0001717115 tem:RyanFukushimaMember 2024-06-30 0001717115 tem:GenomicMember 2023-01-01 2023-06-30 0001717115 tem:DataAndServicesMember 2023-01-01 2023-06-30 0001717115 srt:MaximumMember 2023-01-01 2023-06-30 0001717115 tem:PathosMember us-gaap:SubscriptionArrangementMember 2023-01-01 2023-06-30 0001717115 srt:MinimumMember tem:PathosMember 2023-01-01 2023-06-30 0001717115 tem:SeriesG-3PreferredStockMember us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001717115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001717115 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-06-30 0001717115 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001717115 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001717115 tem:SeriesGThreeRedeemableConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001717115 tem:SeriesGFourRedeemableConvertiblePreferredStockMember 2023-01-01 2023-06-30 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001717115 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001717115 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-06-30 0001717115 tem:AstraZenecaWarrantMember 2023-01-01 2023-06-30 0001717115 tem:SharesIssuableContingentlyToMprikMember 2023-01-01 2023-06-30 0001717115 tem:AmendedAndRestatedConvertiblePromissoryNoteMember 2023-01-01 2023-06-30 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember 2023-01-01 2023-06-30 0001717115 tem:CostOfRevenueGenomicsMember 2023-01-01 2023-06-30 0001717115 tem:CostOfRevenueDataAndServicesMember 2023-01-01 2023-06-30 0001717115 tem:TechnologyResearchAndDevelopmentMember 2023-01-01 2023-06-30 0001717115 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-06-30 0001717115 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-06-30 0001717115 us-gaap:RestrictedStockUnitsRSUMember tem:TwoThousandAndFifteenStockOptionPlanMember 2023-01-01 2023-06-30 0001717115 tem:GenomicsProductMember 2023-01-01 2023-06-30 0001717115 us-gaap:ThirdPartyPayorMember tem:ClinicalOrderMember 2023-01-01 2023-06-30 0001717115 us-gaap:SelfPayMember tem:GenomicsProductMember 2023-01-01 2023-06-30 0001717115 tem:InsightsProductMember 2023-01-01 2023-06-30 0001717115 tem:TrialsProductMember 2023-01-01 2023-06-30 0001717115 tem:DataAndOtherMember 2023-01-01 2023-06-30 0001717115 tem:MpirikMember 2023-01-01 2023-06-30 0001717115 tem:DeidendifiedDataThroughAdditionalAgreementMember tem:LicensedDataMember 2023-01-01 2023-06-30 0001717115 tem:ResearchAndDevelopmentProcessMember tem:LicensedDataMember 2023-01-01 2023-06-30 0001717115 tem:WarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001717115 tem:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001717115 us-gaap:FairValueInputsLevel3Member 2023-01-01 2023-06-30 0001717115 tem:OperatingCostAndExpensesMember 2023-01-01 2023-06-30 0001717115 tem:GenomicMember 2023-04-01 2023-06-30 0001717115 tem:DataAndServicesMember 2023-04-01 2023-06-30 0001717115 srt:MaximumMember 2023-04-01 2023-06-30 0001717115 tem:PathosMember us-gaap:SubscriptionArrangementMember 2023-04-01 2023-06-30 0001717115 srt:MinimumMember tem:PathosMember 2023-04-01 2023-06-30 0001717115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001717115 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001717115 tem:AmendedAndRestatedConvertiblePromissoryNoteMember 2023-04-01 2023-06-30 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember 2023-04-01 2023-06-30 0001717115 tem:TechnologyResearchAndDevelopmentMember 2023-04-01 2023-06-30 0001717115 tem:CostOfRevenueDataAndServicesMember 2023-04-01 2023-06-30 0001717115 tem:CostOfRevenueGenomicsMember 2023-04-01 2023-06-30 0001717115 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-04-01 2023-06-30 0001717115 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-01 2023-06-30 0001717115 us-gaap:RestrictedStockUnitsRSUMember tem:TwoThousandAndFifteenStockOptionPlanMember 2023-04-01 2023-06-30 0001717115 tem:GenomicsProductMember 2023-04-01 2023-06-30 0001717115 us-gaap:ThirdPartyPayorMember tem:ClinicalOrderMember 2023-04-01 2023-06-30 0001717115 us-gaap:SelfPayMember tem:GenomicsProductMember 2023-04-01 2023-06-30 0001717115 tem:InsightsProductMember 2023-04-01 2023-06-30 0001717115 tem:TrialsProductMember 2023-04-01 2023-06-30 0001717115 tem:DataAndOtherMember 2023-04-01 2023-06-30 0001717115 tem:DeidendifiedDataThroughAdditionalAgreementMember tem:LicensedDataMember 2023-04-01 2023-06-30 0001717115 us-gaap:FairValueInputsLevel3Member 2023-04-01 2023-06-30 0001717115 tem:OperatingCostAndExpensesMember 2023-04-01 2023-06-30 0001717115 tem:GenomicMember 2024-01-01 2024-06-30 0001717115 tem:DataAndServicesMember 2024-01-01 2024-06-30 0001717115 srt:MaximumMember 2024-01-01 2024-06-30 0001717115 tem:PathosMember us-gaap:SubscriptionArrangementMember 2024-01-01 2024-06-30 0001717115 srt:MinimumMember tem:PathosMember 2024-01-01 2024-06-30 0001717115 tem:SeriesG-3PreferredStockMember us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 tem:Seriesg4preferredstockMember us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 tem:SeriesG-5PreferredStockMember us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-06-30 0001717115 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001717115 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 us-gaap:CommonClassAMember us-gaap:CommonStockMember us-gaap:IPOMember 2024-01-01 2024-06-30 0001717115 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2024-01-01 2024-06-30 0001717115 us-gaap:IPOMember 2024-01-01 2024-06-30 0001717115 tem:ExcerciseOfWarrantsMember us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 tem:ExcerciseOfWarrantsMember us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 tem:ExcerciseOfWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-06-30 0001717115 tem:ExcerciseOfWarrantsMember 2024-01-01 2024-06-30 0001717115 tem:SeriesGThreeRedeemableConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001717115 tem:SeriesGFourRedeemableConvertiblePreferredStockMember 2024-01-01 2024-06-30 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 us-gaap:RetainedEarningsMember 2024-01-01 2024-06-30 0001717115 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 us-gaap:RestrictedStockUnitsRSUMember us-gaap:IPOMember 2024-01-01 2024-06-30 0001717115 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-06-30 0001717115 tem:AstraZenecaWarrantMember 2024-01-01 2024-06-30 0001717115 tem:SengineHoldbackLiabilityMember 2024-01-01 2024-06-30 0001717115 tem:ContingentConsiderationPayableOnAccountOfBusinessCombinationMember 2024-01-01 2024-06-30 0001717115 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-06-30 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember 2024-01-01 2024-06-30 0001717115 tem:AmendedAndRestatedConvertiblePromissoryNoteMember 2024-01-01 2024-06-30 0001717115 tem:CostOfRevenueGenomicsMember 2024-01-01 2024-06-30 0001717115 tem:TechnologyResearchAndDevelopmentMember 2024-01-01 2024-06-30 0001717115 tem:CostOfRevenueDataAndServicesMember 2024-01-01 2024-06-30 0001717115 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-06-30 0001717115 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-06-30 0001717115 us-gaap:RestrictedStockUnitsRSUMember tem:TwoThousandAndFifteenPlanMember 2024-01-01 2024-06-30 0001717115 us-gaap:RestrictedStockUnitsRSUMember tem:TwoThousandAndFifteenStockOptionPlanMember 2024-01-01 2024-06-30 0001717115 tem:GenomicsProductMember 2024-01-01 2024-06-30 0001717115 us-gaap:ThirdPartyPayorMember tem:ClinicalOrderMember 2024-01-01 2024-06-30 0001717115 us-gaap:SelfPayMember tem:GenomicsProductMember 2024-01-01 2024-06-30 0001717115 tem:InsightsProductMember 2024-01-01 2024-06-30 0001717115 tem:TrialsProductMember 2024-01-01 2024-06-30 0001717115 tem:DataAndOtherMember 2024-01-01 2024-06-30 0001717115 us-gaap:CommonClassBMember 2024-01-01 2024-06-30 0001717115 srt:MinimumMember us-gaap:CommonClassBMember 2024-01-01 2024-06-30 0001717115 srt:MaximumMember us-gaap:CommonClassBMember 2024-01-01 2024-06-30 0001717115 tem:ResearchAndDevelopmentProcessMember tem:LicensedDataMember 2024-01-01 2024-06-30 0001717115 tem:ContingentConsiderationMember 2024-01-01 2024-06-30 0001717115 tem:ContingentConsiderationMember us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 tem:ContingentConsiderationMember us-gaap:FairValueInputsLevel1Member us-gaap:CommonStockMember 2024-01-01 2024-06-30 0001717115 us-gaap:WarrantMember 2024-01-01 2024-06-30 0001717115 tem:WarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-06-30 0001717115 tem:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-06-30 0001717115 us-gaap:FairValueInputsLevel3Member 2024-01-01 2024-06-30 0001717115 tem:OperatingCostAndExpensesMember 2024-01-01 2024-06-30 0001717115 tem:InvestmentInRecursionPharmaceuticalsClassACommonStockMember 2024-01-01 2024-06-30 0001717115 tem:EricLefkofskyMember 2024-01-01 2024-06-30 0001717115 tem:RyanBartolucciMember 2024-01-01 2024-06-30 0001717115 tem:JamesRogersMember 2024-01-01 2024-06-30 0001717115 tem:AndrewPolovinMember 2024-01-01 2024-06-30 0001717115 tem:ErikPhelpsMember 2024-01-01 2024-06-30 0001717115 tem:RyanFukushimaMember 2024-01-01 2024-06-30 0001717115 tem:GenomicMember 2024-04-01 2024-06-30 0001717115 tem:DataAndServicesMember 2024-04-01 2024-06-30 0001717115 srt:MaximumMember 2024-04-01 2024-06-30 0001717115 tem:PathosMember us-gaap:SubscriptionArrangementMember 2024-04-01 2024-06-30 0001717115 srt:MinimumMember tem:PathosMember 2024-04-01 2024-06-30 0001717115 tem:SeriesG-5PreferredStockMember us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001717115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-01 2024-06-30 0001717115 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001717115 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001717115 us-gaap:CommonClassAMember us-gaap:CommonStockMember us-gaap:IPOMember 2024-04-01 2024-06-30 0001717115 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2024-04-01 2024-06-30 0001717115 us-gaap:IPOMember 2024-04-01 2024-06-30 0001717115 tem:ExcerciseOfWarrantsMember us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001717115 tem:ExcerciseOfWarrantsMember us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001717115 tem:ExcerciseOfWarrantsMember 2024-04-01 2024-06-30 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001717115 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001717115 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001717115 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001717115 tem:AmendedAndRestatedConvertiblePromissoryNoteMember 2024-04-01 2024-06-30 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember 2024-04-01 2024-06-30 0001717115 tem:CostOfRevenueDataAndServicesMember 2024-04-01 2024-06-30 0001717115 tem:TechnologyResearchAndDevelopmentMember 2024-04-01 2024-06-30 0001717115 tem:CostOfRevenueGenomicsMember 2024-04-01 2024-06-30 0001717115 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-04-01 2024-06-30 0001717115 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-01 2024-06-30 0001717115 us-gaap:RestrictedStockUnitsRSUMember tem:TwoThousandAndFifteenStockOptionPlanMember 2024-04-01 2024-06-30 0001717115 us-gaap:RestrictedStockUnitsRSUMember tem:TwoThousandAndFifteenStockOptionPlanMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-04-01 2024-06-30 0001717115 tem:GenomicsProductMember 2024-04-01 2024-06-30 0001717115 us-gaap:ThirdPartyPayorMember tem:ClinicalOrderMember 2024-04-01 2024-06-30 0001717115 us-gaap:SelfPayMember tem:GenomicsProductMember 2024-04-01 2024-06-30 0001717115 tem:TrialsProductMember 2024-04-01 2024-06-30 0001717115 tem:DataAndOtherMember 2024-04-01 2024-06-30 0001717115 tem:InsightsProductMember 2024-04-01 2024-06-30 0001717115 us-gaap:FairValueInputsLevel3Member 2024-04-01 2024-06-30 0001717115 tem:OperatingCostAndExpensesMember 2024-04-01 2024-06-30 0001717115 us-gaap:CommonClassAMember 2024-04-01 2024-06-30 0001717115 tem:TermLoanAgreementWithAresCapitalCorporationMember 2023-06-30 0001717115 tem:TermLoanAmendmentAgreementOneWithAresCapitalCorporationMember 2023-06-30 0001717115 us-gaap:CommonClassAMember us-gaap:IPOMember 2024-06-17 0001717115 us-gaap:RestrictedStockUnitsRSUMember us-gaap:IPOMember 2024-06-17 0001717115 us-gaap:CommonClassBMember us-gaap:IPOMember 2024-06-17 0001717115 us-gaap:IPOMember 2024-06-17 0001717115 us-gaap:CommonClassBMember 2024-06-17 0001717115 tem:CommercializationAndReferenceLaboratoryAgreementMemberWithPersonalisIncMember tem:PersonalisIncMember 2023-11-30 0001717115 tem:SengineMember 2023-10-03 2023-10-03 0001717115 tem:SengineMember us-gaap:NonvotingCommonStockMember 2023-10-03 2023-10-03 0001717115 tem:SengineMember 2023-10-03 0001717115 tem:SengineMember srt:MaximumMember 2023-10-03 0001717115 tem:SengineMember us-gaap:NonvotingCommonStockMember 2024-02-01 2024-02-29 0001717115 tem:MpirikMember 2023-03-08 2023-03-08 0001717115 tem:MpirikMember us-gaap:NonvotingCommonStockMember 2023-03-08 2023-03-08 0001717115 us-gaap:RestrictedStockUnitsRSUMember tem:MpirikMember 2023-03-08 2023-03-08 0001717115 tem:MpirikMember 2023-03-08 0001717115 us-gaap:OtherCurrentLiabilitiesMember tem:MpirikMember 2023-03-08 0001717115 tem:MpirikMember 2024-01-01 0001717115 tem:ArterysMember 2022-10-03 2022-10-03 0001717115 tem:ArterysMember 2022-10-03 0001717115 us-gaap:CommonClassAMember 2021-12-31 0001717115 us-gaap:CommonClassBMember 2021-12-31 0001717115 us-gaap:NonvotingCommonStockMember 2021-12-31 0001717115 us-gaap:CommonClassAMember tem:MasterServicesAgreementWithAstraZenecaAsAmendedMember 2021-12-31 0001717115 us-gaap:CommonClassAMember 2022-04-30 0001717115 tem:ExcerciseOfWarrantsMember tem:ClassAVotingStockMember 2023-12-08 2023-12-08 0001717115 tem:ExerciseOfWarrantsMember us-gaap:CommonClassAMember 2023-12-08 2023-12-08 0001717115 tem:WarrantsConvertibleIntoClassACommonStockMember tem:AllenAndCompanyLlcMember 2023-12-08 0001717115 us-gaap:NonvotingCommonStockMember us-gaap:TreasuryStockCommonMember 2023-01-01 2023-01-31 0001717115 tem:SeriesGThreeRedeemableConvertiblePreferredStockMember 2023-01-01 2023-01-31 0001717115 tem:SeriesGThreeRedeemableConvertiblePreferredStockMember 2024-01-01 2024-01-31 0001717115 tem:SeriesGFourRedeemableConvertiblePreferredStockMember 2024-01-01 2024-01-31 0001717115 tem:SeriesGFiveRedeemableConvertiblePreferredStockMember 2024-04-01 2024-04-30 0001717115 tem:SeriesGFiveRedeemableConvertiblePreferredStockMember 2024-04-30 0001717115 tem:TwoThousandAndTwentyFourEquityIncentivePlanMember us-gaap:CommonClassAMember 2024-07-01 2024-07-31 0001717115 tem:TermLoanAgreementWithAresCapitalCorporationMember 2022-09-22 0001717115 tem:TermLoanAmendmentAgreementOneWithAresCapitalCorporationMember 2023-04-25 0001717115 tem:TermLoanAmendmentAgreementTwoWithAresCapitalCorporationMember 2023-10-11 2023-10-11 0001717115 tem:TermLoanAmendmentAgreementTwoWithAresCapitalCorporationMember tem:SOFROneMember 2023-10-11 2023-10-11 0001717115 us-gaap:FederalFundsEffectiveSwapRateMember 2023-10-11 2023-10-11 0001717115 us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-10-11 2023-10-11 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember us-gaap:BaseRateMember 2023-10-11 2023-10-11 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember tem:BaseRateOneMember 2023-10-11 2023-10-11 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-10-11 2023-10-11 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember tem:TermSecuredOvernightFinancingRateOneMember 2023-10-11 2023-10-11 0001717115 tem:TermLoanAmendmentAgreementTwoWithAresCapitalCorporationMember 2023-10-11 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember 2023-10-11 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember tem:TwelveMonthsEndedThirtyFirstOfDecemberTwoThousandAndTwentyFourMember srt:ScenarioForecastMember 2024-01-01 2024-12-31 0001717115 tem:TermLoanAgreementIncludingAmendmentAgreementOneAndTwoWithAresCapitalCorporationMember tem:TwelveMonthsEndedThirtyFirstOfDecemberTwoThousandAndTwentyFiveMember srt:ScenarioForecastMember 2025-01-01 2025-12-31 0001717115 us-gaap:ConvertibleNotesPayableMember 2020-06-22 0001717115 tem:AmendedAndRestatedConvertiblePromissoryNoteMember 2020-06-22 0001717115 us-gaap:ConvertibleNotesPayableMember tem:SeriesGTwoRedeemableConvertiblePreferredStockMember 2020-11-19 2020-11-19 0001717115 us-gaap:ConvertibleNotesPayableMember tem:SeriesGTwoRedeemableConvertiblePreferredStockMember 2020-11-19 0001717115 tem:AmendedAndRestatedConvertiblePromissoryNoteMember 2020-06-22 2020-06-22 0001717115 us-gaap:ConvertibleNotesPayableMember 2020-06-22 2020-06-22 0001717115 tem:ContingentConsiderationMember 2023-01-01 2023-12-31 0001717115 us-gaap:RelatedPartyMember 2018-01-01 2018-12-31 0001717115 tem:PathosMember us-gaap:WarrantMember 2021-08-19 2021-08-19 0001717115 tem:PathosMember us-gaap:WarrantMember 2021-08-19 0001717115 tem:PathosMember us-gaap:SubscriptionArrangementMember 2021-08-19 0001717115 us-gaap:CommonClassAMember us-gaap:IPOMember 2024-06-17 2024-06-17 0001717115 tem:SeriesAToSeriesGRedeemableConvertiblePreferredStockOtherThanClassBMember 2024-06-17 2024-06-17 0001717115 tem:SeriesBBOneAndBTwoRedeemableConvertiblePreferredStockMember 2024-06-17 2024-06-17 0001717115 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CommonClassAMember 2024-06-17 2024-06-17 0001717115 us-gaap:RestrictedStockUnitsRSUMember us-gaap:IPOMember 2024-06-17 2024-06-17 0001717115 tem:InvestorAgreementWithSeriesGThreeRedeemablePreferredStockholdersMember tem:SeriesGThreeRedeemableConvertiblePreferredStockMember 2024-06-17 2024-06-17 0001717115 tem:CommercializationAndReferenceLaboratoryAgreementMemberWithPersonalisIncMember 2023-11-30 2023-11-30 0001717115 us-gaap:CommonClassAMember 2022-10-01 2022-10-31 0001717115 tem:ClassAVotingCommonStockMember 2024-06-16 2024-06-16 0001717115 tem:ClassAVotingStockMember 2024-06-16 2024-06-16 0001717115 us-gaap:CommonClassBMember 2024-08-06 0001717115 us-gaap:CommonClassAMember 2024-08-06 0001717115 tem:SeriesGFiveRedeemableConvertiblePreferredStockMember 2023-10-01 2023-10-31 0001717115 tem:SeriesGFiveRedeemableConvertiblePreferredStockMember 2023-10-31 0001717115 tem:CorporateJointVentureBetweenTheCompanyAndTheSoftBankGroupJapanMember us-gaap:SubsequentEventMember 2024-07-18 0001717115 tem:InvestmentInJapanJointVenturePursuantToJointVentureAgreementMember us-gaap:SubsequentEventMember 2024-07-18 0001717115 us-gaap:CoVenturerMember tem:InvestmentInJapanJointVenturePursuantToJointVentureAgreementMember us-gaap:SubsequentEventMember 2024-07-18 0001717115 tem:CorporateJointVentureBetweenTheCompanyAndTheSoftBankGroupJapanMember us-gaap:SubsequentEventMember tem:IntellectualPropertyLicenseAgreementMember 2024-07-18 2024-07-18 0001717115 tem:CorporateJointVentureBetweenTheCompanyAndTheSoftBankGroupJapanMember us-gaap:SubsequentEventMember tem:DataLicenseAgreementMember 2024-07-18 2024-07-18 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2022-12-31 0001717115 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001717115 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2022-12-31 0001717115 us-gaap:TreasuryStockCommonMember 2022-12-31 0001717115 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001717115 us-gaap:RetainedEarningsMember 2022-12-31 0001717115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001717115 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001717115 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2023-06-30 0001717115 us-gaap:TreasuryStockCommonMember 2023-06-30 0001717115 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001717115 us-gaap:RetainedEarningsMember 2023-06-30 0001717115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2023-06-30 0001717115 tem:WarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001717115 tem:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2022-12-31 0001717115 tem:WarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001717115 tem:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2023-06-30 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2023-03-31 0001717115 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-03-31 0001717115 us-gaap:TreasuryStockCommonMember 2023-03-31 0001717115 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001717115 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2023-03-31 0001717115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001717115 us-gaap:RetainedEarningsMember 2023-03-31 0001717115 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001717115 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2023-06-30 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2023-12-31 0001717115 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-12-31 0001717115 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2023-12-31 0001717115 us-gaap:TreasuryStockCommonMember 2023-12-31 0001717115 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001717115 us-gaap:RetainedEarningsMember 2023-12-31 0001717115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001717115 us-gaap:RestrictedStockUnitsRSUMember tem:TwoThousandAndFifteenPlanMember 2023-12-31 0001717115 us-gaap:RestrictedStockUnitsRSUMember tem:TwoThousandAndFifteenPlanMember 2024-06-30 0001717115 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-06-30 0001717115 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2024-06-30 0001717115 us-gaap:TreasuryStockCommonMember 2024-06-30 0001717115 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001717115 us-gaap:RetainedEarningsMember 2024-06-30 0001717115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001717115 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-06-30 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2024-06-30 0001717115 tem:WarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001717115 tem:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2023-12-31 0001717115 tem:WarrantLiabilityMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001717115 tem:ContingentConsiderationMember us-gaap:FairValueInputsLevel3Member 2024-06-30 0001717115 us-gaap:RedeemableConvertiblePreferredStockMember us-gaap:CommonStockMember 2024-03-31 0001717115 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2024-03-31 0001717115 us-gaap:CommonClassBMember us-gaap:CommonStockMember 2024-03-31 0001717115 us-gaap:TreasuryStockCommonMember 2024-03-31 0001717115 us-gaap:NonvotingCommonStockMember us-gaap:CommonStockMember 2024-03-31 0001717115 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001717115 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001717115 us-gaap:RetainedEarningsMember 2024-03-31 xbrli:shares iso4217:USD xbrli:pure utr:Year utr:Day iso4217:JPY iso4217:USD xbrli:shares utr:Y
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
10-Q
 
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended
June 30
, 2024
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from
     
to
     
Commission File No. 001-42130
 
 
Tempus AI, Inc.
(Exact name of registrant as specified in its charter)
 
 
 
Delaware
 
47-4903308
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
600 West Chicago Avenue, Suite 510
Chicago,
IL
60654
(Address of Principal Executive Offices, Zip Code)
(800) 976-5448
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
 
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Class A common stock, $0.0001 par value per share
 
TEM
 
The Nasdaq Stock Market LLC
 
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes
 ☐ No ☒
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer      Accelerated filer  
Non-accelerated
filer
     Smaller reporting company  
     Emerging growth company  
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act): Yes ☐ No 
As of August 6,
2024
,
there were 149,274,923
shares of Class A common stock and 5,043,789 shares of Class B common stock, each with a par value of $0.0001 per share, outstanding. 
 
 
 


         Page  

Part I – Condensed Consolidated Financial Statements (unaudited)

     1  

Item 1.

  Condensed Consolidated Quarterly Financial Statements (Unaudited)      1  
 

Condensed Consolidated Balance Sheets

     2  
 

Condensed Consolidated Statements of Operations and Comprehensive Loss

     4  
 

Condensed Consolidated Statements of Cash Flows

     5  
 

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock, Common Stock and Stockholders’ Equity (Deficit)

     7  
 

Notes to Condensed Consolidated Financial Statements

     9  

Item 2.

  Management’s Discussion and Analysis of Financial Condition and Results of Operations      32  

Item 3.

  Quantitative and Qualitative Disclosures about Market Risk      57  

Item 4.

  Controls and Procedures      58  

Part II – Other Information

     59  

Item 1.

  Legal Proceedings      59  

Item 1A.

  Risk Factors      59  

Item 2.

  Unregistered Sales of Equity Securities and Use of Proceeds      138  

Item 3.

  Defaults Upon Senior Securities      138  

Item 4.

  Mine Safety Disclosures      138  

Item 5.

  Other Information      138  

Item 6.

  Exhibits      139  

Signatures

     140  


1P3Y
Tempus AI, Inc.
Condensed Consolidated Quarterly Financial Statements (Unaudited)
June 30, 2024

Tempus AI, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(in thousands, except share and per share amounts)
 
 
  
June 30, 2024
 
  
December 31, 2023
 
Assets
  
  
Current Assets
 
     
 
     
Cash and cash equivalents
 
$
478,811
 
 
 
 
 
 
 
 
 
$
165,767
 
Accounts receivable, net of allowances of $1,092 and $1,115 at June 30, 2024 and December 31, 2023, respectively
 
 
118,106
 
 
 
94,462
 
Inventory
 
 
32,690
 
 
 
28,845
 
Warrant asset
 
 
800
 
 
 
5,070
 
Prepaid expenses and other current assets
 
 
29,704
 
 
 
17,295
 
Marketable equity securities
 
 
11,255
 
 
 
31,807
 
Deferred offering costs
 
 
 
 
 
7,085
 
 
 
 
 
 
 
 
 
 
Total current assets
 
$
671,366
 
 
$
350,331
 
Property and equipment, net
 
 
60,539
 
 
 
61,681
 
Goodwill
 
 
73,345
 
 
 
73,354
 
Warrant asset, less current portion
 
 
1,500
 
 
 
4,930
 
Intangible assets, net
 
 
16,252
 
 
 
21,916
 
Investments and other assets
 
 
7,677
 
 
 
8,971
 
Warrant contract asset, less current portion
 
 
19,077
 
 
 
21,499
 
Operating lease right-of-use assets
 
 
13,994
 
 
 
20,530
 
Restricted cash
 
 
861
 
 
 
840
 
 
 
 
 
 
 
 
 
 
Total Assets
 
$
864,611
 
 
$
564,052
 
 
 
 
 
 
 
 
 
 
Liabilities, Convertible redeemable preferred stock, and Stockholders’ 
equity (
deficit
)
 
     
 
     
Current Liabilities
 
     
 
     
Accounts payable
 
 
28,646
 
 
 
54,421
 
Accrued expenses
 
 
85,185
 
 
 
82,517
 
Deferred revenue
 
 
50,905
 
 
 
64,860
 
Other current liabilities
 
 
7,273
 
 
 
8,213
 
Operating lease liabilities
 
 
5,828
 
 
 
6,437
 
Accrued data licensing fees
 
 
3,727
 
 
 
6,382
 
Accrued dividends
 
 
 
 
 
9,797
 
 
 
 
 
 
 
 
 
 
Total current liabilities
 
$
181,564
 
 
$
232,627
 
Operating lease liabilities, less current portion
 
 
27,238
 
 
 
32,040
 
Convertible promissory note
 
 
180,648
 
 
 
193,124
 
Warrant liability
 
 
33,600
 
 
 
34,500
 
Other long-term liabilities
 
 
16,790
 
 
 
19,751
 
Interest payable
 
 
62,608
 
 
 
55,321
 
Long-term debt, net
 
 
261,853
 
 
 
256,541
 
Deferred revenue, less current portion
 
 
2,059
 
 
 
16,768
 
 
 
 
 
 
 
 
 
 
Total Liabilities
 
$
766,360
 
 
$
840,672
 
 
 
 
 
 
 
 
 
 
Commitments and contingencies (Note
7
)
 
     
 
     
Convertible redeemable preferred stock, $0.0001 par value, no and 69,803,765 shares authorized at
June 30, 2024 and December 31, 2023, respectively; no and 63,525,953 shares issued and outstanding
at June 30, 2024 and December 31, 2023, respectively; aggregate liquidation preference of $0 and
$1,130,429 at
 
June 30, 2024 and December 31, 2023, respectively
 
 
 
 
 
1,105,543
 
The accompanying notes are an integral part of these
condensed 
consolidated financial statements.
 
2

Stockholders’ equity (deficit)
  
 
Class A Voting Common Stock, $0.0001 par value, 1,000,000,000 and 200,228,024 shares
authorized at June 30, 2024 and December 31, 2023, respectively; 149,274,923 and
58,367,961 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively
   $ 15     $ 6  
Class B Voting Common Stock, $0.0001 par value, 5,500,000 and 5,374,899 shares authorized at
June 30, 2024 and December 31, 2023, respectively; 5,043,789 and no shares issued and
outstanding at June 30, 2024 and December 31, 2023, respectively
     1        
Non-voting Common Stock, $0.0001 par value, no and 66,946,627 shares authorized at June 30,
2024 and December 31, 2023, respectively;
no
shares issued and outstanding at June 30, 2024,
and 5,205,802 shares issued and 5,060,336 shares outstanding at December 31, 2023
           0  
Treasury Stock, 145,466 shares at June 30, 2024 and December 31, 2023, at cost
     (3,602     (3,602
Additional Paid-In Capital
     2,163,911       18,345  
Accumulated Other Comprehensive (Loss) Income
     (94 )     5  
Accumulated deficit
     (2,061,980 )     (1,396,917
  
 
 
   
 
 
 
Total Stockholders’ equity (deficit)
   $ 98,251     $ (1,382,163
  
 
 
   
 
 
 
Total Liabilities, Convertible redeemable preferred stock, and Stockholders’ equity (deficit)
   $ 864,611     $ 564,052  
  
 
 
   
 
 
 
The accompanying notes are an integral part of these
condensed 
consolidated financial statements.
 
3

Tempus AI, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENS
IVE
LOSS
(Unaudited)
(in thousands, except per share amounts)
 
 
  
Three Months Ended June 30,
 
 
Six Months Ended June 30,
 
 
  
2024
 
 
2023
 
 
2024
 
 
2023
 
Net revenue
        
Genomics
   $ 112,324     $ 91,924     $ 214,893     $ 173,982  
Data and services
     53,645       40,493       96,896       74,059  
  
 
 
   
 
 
   
 
 
   
 
 
 
Total net revenue
   $ 165,969     $ 132,417     $ 311,789     $ 248,041  
Cost and operating expenses
        
Cost of revenues, genomics
     68,324       46,961       121,159       92,241  
Cost of revenues, data and services
     22,132       13,807       37,420       25,200  
Technology research and development
     77,908       23,427       104,975       46,329  
Research and development
     68,025       22,171       92,365       43,034  
Selling, general and administrative
     463,072       71,189       542,636       140,236  
Total cost and operating expenses
     699,461       177,555       898,555       347,040  
  
 
 
   
 
 
   
 
 
   
 
 
 
Loss from operations
   $ (533,492 )   $ (45,138   $ (586,766 )   $ (98,999
  
 
 
   
 
 
   
 
 
   
 
 
 
Interest income
     1,718       1,957       2,749       4,381  
Interest expense
     (13,295 )     (11,712     (26,533 )     (20,903
Other (expense) income, net
     (7,048 )     (766     (6,299 )     5,622  
  
 
 
   
 
 
   
 
 
   
 
 
 
Loss before provision for income taxes
   $ (552,117 )   $ (55,659   $ (616,849 )   $ (109,899
Provision for income taxes
     (95 )     (3     (106 )     (9
Losses from equity method investments
           (170           (301
  
 
 
   
 
 
   
 
 
   
 
 
 
Net Loss
   $ (552,212 )   $ (55,832   $ (616,955 )   $ (110,209
  
 
 
   
 
 
   
 
 
   
 
 
 
Dividends on Series A, B, B-1, B-2, C, D, E, F, G, G-3, and G-4 preferred shares
     (11,540 )     (10,897     (39,347 )     (21,566
Cumulative Undeclared Dividends on Series C preferred shares
     (668 )     (745     (1,174 )     (1,466
  
 
 
   
 
 
   
 
 
   
 
 
 
Net loss attributable to common shareholders, basic and diluted
     (564,420 )     (67,474     (657,476 )     (133,241
Net loss per share attributable to common shareholders, basic and diluted
   $ (6.86 )   $ (1.07   $ (9.02
)
  $ (2.11
Weighted-average shares outstanding used to compute net loss per share, basic and diluted
     82,325       63,286     72,930     63,257  
  
 
 
   
 
 
   
 
 
   
 
 
 
Comprehensive Loss, net of tax
        
Net loss
   $ (552,212 )   $ (55,832   $ (616,955 )   $ (110,209
Foreign currency translation adjustment
     (43 )     53       (99 )     25  
  
 
 
   
 
 
   
 
 
   
 
 
 
Comprehensive loss
   $ (552,255 )   $ (55,779   $ (617,054 )   $ (110,184
  
 
 
   
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of these
condensed 
consolidated financial statements.
 
4

Tempus AI, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(in thousands, except share and per share amounts)
 
 
  
Six Months Ended June 30,
 
 
  
2024
 
 
2023
 
Operating activities
    
Net loss
   $ (616,955 )
 
  $ (110,209
Adjustments to reconcile net loss to net cash used in operating activities
    
Change in fair value of warrant liability
   $ (900 )   $ (5,700
Stock-based compensation
     488,313        
Gain on warrant exercise
     (173 )      
Gain on marketable equity securities
     (2,541 )      
Amortization of original issue discount
     691       489  
Amortization of deferred financing fees
     255       255  
Change in fair value of contingent consideration
     165        
Amortization of warrant contract asset
     2,422       3,307  
Depreciation and amortization
     18,348       16,185  
Provision for bad debt expense
     327       1,376  
Change in fair value of warrant asset
     7,700        
Loss from equity-method investments
           301  
Amortization of finance right-of-use lease assets
           190  
Non-cash operating lease costs
     3,252       3,382  
Minimum accretion expense
     92       187  
Impairment of intangible assets
           7,359  
PIK interest added to principal
     4,366       297  
Change in assets and liabilities
    
Accounts receivable
     (23,971 )     (6,850
Inventory
     (3,845 )     (5,101
Prepaid expenses and other current assets
     (12,409 )     (1,634
Investments and other assets
     1,294       (4,528
Accounts payable
     (33,371 )     (4,195
Deferred revenue
     (28,669 )     (19,974
Accrued data licensing fees
     (2,749 )     (7,608
Accrued expenses & other
     (2,805 )     8,125  
Interest payable
     7,287       7,611  
Operating lease liabilities
     (4,582 )     (4,352
  
 
 
   
 
 
 
Net cash used in operating activities
   $ (198,458 )   $ (121,087
  
 
 
   
 
 
 
Investing activities
    
Purchases of property and equipment
   $ (14,116 )   $ (15,906
Proceeds from sale of marketable equity securities
     23,098        
Business combinations, net of cash acquired (Note
4
)
           (2,869
  
 
 
   
 
 
 
Net cash provided by (used in) investing activities
   $ 8,982     $ (18,775
  
 
 
   
 
 
 
Financing activities
    
Proceeds from issuance of common stock in connection with initial public offering, net of
underwriting
discounts and 
commissions
   $ 381,951     $  
Tax withholding related to net share settlement of restricted stock units
     (69,918 )      
Issuance of Series G-5 Preferred Stock
     199,750        
Principal payments on finance lease liabilities
           (192
Purchase of treasury stock
           (3,602
Payment of deferred offering costs
     (2,714 )     (151
Dividends paid
     (5,625 )     (5,625
Proceeds from long-term debt, net of original issue discount
           48,750  
Payment of indemnity holdback related to acquisition
     (813 )      
  
 
 
   
 
 
 
Net cash provided by financing activities
   $ 502,631     $ 39,180  
  
 
 
   
 
 
 
Effect of foreign exchange rates on cash
   $ (90 )   $ 28  
  
 
 
   
 
 
 
The accompanying notes are an integral part of these
condensed 
consolidated financial statements.
 
5

Net increase (decrease) in Cash, Cash Equivalents and Restricted Cash
  
$
313,065
 
 
$
(100,654
Cash, cash equivalents and restricted cash, beginning of period
  
 
166,607
 
 
 
303,731
 
  
 
 
 
 
 
 
 
Cash, cash equivalents and restricted cash, end of period
  
$
479,672
 
 
$
203,077
 
  
 
 
 
 
 
 
 
Cash, Cash Equivalents and Restricted Cash are Comprised of:
  
 
Cash and cash
equivalents
   $ 478,811      $ 202,266  
Restricted cash and cash equivalents
     861       811  
  
 
 
   
 
 
 
Total cash, cash equivalents and restricted cash
   $ 479,672     $ 203,077  
  
 
 
   
 
 
 
Supplemental disclosure of cash flow information
    
Cash paid during the year for interest
   $ 13,921     $ 5,691  
  
 
 
   
 
 
 
Cash paid for income taxes
   $ 89     $ 41  
  
 
 
   
 
 
 
Supplemental disclosure of noncash investing and financing activities
    
Dividends payable
   $ 5,487     $ 4,545  
  
 
 
   
 
 
 
Purchases of property and equipment, accrued but not paid
   $ 1,108     $ 2,952  
  
 
 
   
 
 
 
Deferred offering costs, accrued but not yet paid
   $ 6,051     $ 2,917  
  
 
 
   
 
 
 
Redemption of convertible promissory note
   $ 12,476     $ 13,926  
  
 
 
   
 
 
 
Non-voting common stock issued in connection with business combinations
   $ 344     $ 4,305  
  
 
 
   
 
 
 
Operating lease liabilities arising from obtaining right-of-use assets
   $     $ 892  
  
 
 
   
 
 
 
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering
   $ 1,348,809     $  
  
 
 
    
 
 
 
Taxes related to net share settlement of restricted stock units not yet paid
   $ 164      $  
  
 
 
   
 
 
 
Reclassificiation of deferred offering costs to additional paid-in capital upon initial public offering
   $ 12,347     $  
  
 
 
    
 
 
 
Issuance of Series G-3 Preferred Stock
   $ 3,809     $ 2,738  
  
 
 
   
 
 
 
Issuance of Series G-4 Preferred Stock
   $ 611     $  
  
 
 
    
 
 
 
The accompanying notes are an integral part of these
condensed 
consolidated financial statements.
 
6

Tempus AI, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE
PREFERRED STOCK, COMMON STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
(in thousands, except share and per share amounts)
 
   
Redeemable
Convertible Preferred
Stock
   
Voting

Common Stock
   
Non-Voting

Common Stock
   
Treasury Stock
   
Additional
Paid-in

Capital
   
Accumulated

Deficit
   
Accumulated Other
Comprehensive

(Loss) Income
   
Total
Stockholders’

Deficit
 
   
Class A
   
Class B
 
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
 
Balance at December 31, 2023
    63,525,953     $ 1,105,543       58,367,961     $ 6       —      $ —        5,205,802     $ 0       (145,466   $ (3,602     18,345     $ (1,396,917   $ 5     $ (1,382,163
Issuance of Series G-3 Preferred Stock
    66,465       3,809       —        —        —        —        —        —        —        —        —        —        —        —   
Issuance of Series G-4 Preferred Stock
    10,666       611       —        —        —        —        —        —        —        —        —        —        —        —   
Issuance of Series G-5 Preferred Stock
    3,489,981       199,750       —        —        —        —        —        —        —        —        —        —        —        —   
Common stock issued in connection with business combinations
    —        —        —        —        —        —        9,141       0       —        —        344       —        —        344  
Dividends
    —        33,669       —        —        —        —        —        —        —        —        —        (39,347     —        (39,347
Issuance of common stock in connection with initial public offering, net of
offering costs,
underwriting discounts and
c
om
missions
    —        —        11,100,000       1       —        —        —        —        —        —        369,603       —        —        369,604  
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering
    (67,093,065     (1,343,382     71,976,178       7       5,043,789      
1
      —        —        —        —        1,357,562       (8,761     —        1,348,809  
Conversion of non-voting common stock to Class A common stock
    —        —        5,069,477       1       —        —        (5,214,943     0       —        —        (1     —        —        0  
Issuance of common stock upon settlement of restricted stock units, net
    —        —        2,651,848       0       —        —        —        —        —        —        (70,082     —        —        (70,082 )
Issuance of common stock upon settlement of warrant
    —        —        109,459       0       —              —        —        —        —        (173     —        —        (173 )
Stock-based compensation expense
    —          —        —        —        —        —        —        —        —        488,313         —        488,313  
Foreign currency translation adjustment
    —        —        —        —        —        —        —        —        —        —        —        —        (99     (99
Net loss
    —        —        —        —        —        —        —        —        —        —        —        (616,955     —        (616,955
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance at June 30, 2024
        $       149,274,923     $ 15       5,043,789     $ 1           $       (145,466   $ (3,602   $ 2,163,911     $ (2,061,980   $ (94   $ 98,251  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
   
Redeemable
Convertible Preferred
Stock
   
Voting

Common Stock
   
Non-Voting

Common Stock
   
Treasury Stock
   
Additional
Paid-in

Capital
   
Accumulated

Deficit
   
Accumulated Other
Comprehensive

(Loss) Income
   
Total
Stockholders’

Deficit
 
   
Class A
   
Class B
 
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
 
Balance at December 31, 2022
    62,692,927     $ 1,026,143       58,367,961     $ 6       —      $ —        4,932,415     $ 0       0     $ —        9,251     $ (1,138,302   $ 18     $ (1,129,027
Issuance of Series
G-3
Preferred Stock
    47,781       2,738       —        —        —        —        —        —        —        —        —        —        —        —   
Foreign currency translation adjustment
    —        —        —        —        —        —        —        —        —        —        —        —        25       25  
Dividends
    —        13,980       —        —        —        —        —        —        —        —        —        (21,566     —        (21,566
Repurchase of
Non-voting
Common Stock
    —        —        —        —        —        —        —        —        (145,466     (3,602     —        —        —        (3,602
Common stock issued in connection with business combination
    —        —        —        —        —        —        130,874       0       —        —        4,305       —        —        4,305  
Net loss
    —        —        —        —        —        —        —        —        —        —        —        (110,209     —        (110,209
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance at June 30, 2023
    62,740,708     $ 1,042,861       58,367,961     $ 6       —      $ —        5,063,289     $ 0       (145,466   $ (3,602   $ 13,556     $ (1,270,077   $ 43     $ (1,260,074
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of these
condensed 
consolidated financial statements.
 
7

Tempus AI, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE
PREFERRED STOCK, COMMON STOCK AND STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
(in thousands, except share and per share amounts)
 
   
Redeemable
Convertible Preferred
Stock
   
Voting

Common Stock
   
Non-Voting

Common Stock
   
Treasury Stock
   
Additional
Paid-in

Capital
   
Accumulated

Deficit
   
Accumulated Other
Comprehensive

(Loss) Income
   
Total
Stockholders’

Deficit
 
   
Class A
   
Class B
 
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
 
Balance at March 31, 2024
    63,603,084     $ 1,134,802       58,367,961     $ 6           $       5,214,943     $ 0       (145,466   $ (3,602   $ 18,689     $ (1,489,467   $ (51   $ (1,474,425
Issuance of Series G-5 Preferred Stock
    3,489,981       199,750       —        —        —        —        —        —        —        —        —        —        —        —   
Dividends
    —        8,830       —        —        —        —        —        —        —        —        —        (11,540     —        (11,540
Issuance of common stock in connection with initial public offering, net of
offering costs,
underwriting discounts and
commissions
    —        —        11,100,000       1       —        —        —        —        —        —        369,603       —        —        369,604  
Conversion of redeemable convertible preferred stock to common stock in connection with initial public offering
    (67,093,065     (1,343,382     71,976,178       7       5,043,789       1       —        —        —        —        1,357,562       (8,761     —        1,348,809  
Conversion of non-voting common stock to Class A common stock
    —        —        5,069,477       1       —        —        (5,214,943     0       —        —        (1     —        —        0  
Issuance of common stock upon settlement of restricted stock units, net
    —        —        2,651,848       0       —        —        —        —        —        —        (70,082     —        —        (70,082
Issuance of common stock upon settlement of warrant
    —        —        109,459       0       —        —        —        —        —        —        (173     —        —        (173
Stock-based compensation expense
    —        —        —        —        —        —        —        —        —        —        488,313       —        —        488,313  
Foreign currency translation adjustment
    —        —        —        —        —        —        —        —        —        —        —        —        (43     (43
Net loss
    —        —        —        —        —        —        —        —        —        —        —        (552,212     —        (552,212
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance at June 30, 2024
        $       149,274,923     $ 15       5,043,789     $ 1           $       (145,466   $ (3,602   $ 2,163,911     $ (2,061,980   $ (94   $ 98,251  
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
   
Redeemable
Convertible Preferred
Stock
   
Voting

Common Stock
   
Non-Voting

Common Stock
   
Treasury Stock
   
Additional
Paid-in

Capital
   
Accumulated

Deficit
   
Accumulated Other
Comprehensive

(Loss) Income
   
Total
Stockholders’

Deficit
 
   
Class A
   
Class B
 
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
   
Units
   
Amount
 
Balance at March 31, 2023
    62,740,708     $ 1,034,321       58,367,961     $ 6           $       5,063,289     $ 0       (145,466   $ (3,602     13,556     $ (1,203,348   $ (10   $ (1,193,398
Foreign currency translation adjustment
    —        —        —        —        —        —        —        —        —        —        —        —        53       53  
Dividends
    —        8,540       —        —        —        —        —        —        —        —        —        (10,897     —        (10,897
Net loss
    —        —        —        —        —        —        —        —        —        —        —        (55,832     —        (55,832
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Balance at June 30, 2023
    62,740,708     $ 1,042,861       58,367,961     $ 6       0     $       5,063,289     $ 0       (145,466   $ (3,602   $ 13,556     $ (1,270,077   $ 43     $ (1,260,074
 
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
The accompanying notes are an integral part of these
condensed 
consolidated financial statements.
 
8

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
1.
DESCRIPTION OF BUSINESS
Company Information
Tempus AI, Inc., together with the subsidiaries through which it conducts business (the “Company”), is a healthcare technology company focused on bringing artificial intelligence and machine learning to healthcare in order to improve the care of patients across multiple diseases. The Company combines the results of laboratory tests with other multimodal datasets to improve patient care by supporting all parties in the healthcare ecosystem, including physicians, researchers, payers, and pharmaceutical companies. The Company primarily derives revenue from selling comprehensive genetic testing to physicians and large academic research institutions, licensing data to third parties, matching patients to clinical trials, and related services.
The Company, based in Chicago, Illinois, was founded by Eric P. Lefkofsky, the Company’s CEO and Executive Chairman, and evolved from a business Mr. Lefkofsky founded called Bioin. Bioin originally was established as a limited liability company. Effective September 21, 2015, Bioin converted its legal form to a corporation organized and existing under the General Corporation Law of the State of Delaware. Bioin subsequently changed its legal name to Tempus Health, Inc. in September 2015, to Tempus Labs, Inc. in October 2016 and to Tempus AI, Inc. in December 2023.
Initial Public Offering
On June 13, 2024, the Company’s
 registration statement relating to its
 
initial public offering (the “IPO”) was declared effective and its Class A common stock began trading on the Nasdaq Global Select Market on June 14, 2024. On June 17, 2024, the Company completed its IPO in which it issued and sold 11,100,000 shares of Class A common stock, at a public offering price of $37.00 per share. The Company received net proceeds of $382.0 million after deducting underwriting discounts and
commissions
of $28.7 million.
In connection with the closing of the IPO, all shares of the Company’s then-outstanding redeemable convertible preferred stock, other than the Company’s Series B redeemable convertible preferred stock, converted into an aggregate of
66,309,550
shares of Class A common stock. The Company’s Series B redeemable convertible preferred stock converted on a one-for-one basis into an aggregate of
5,374,899
shares of Class B common stock. Subsequently,
331,110
shares of Class B common stock were automatically converted into shares of Class A common stock, such that there are 
5,043,789
shares of Class B common stock outstanding immediately following the IPO. The Company issued an additional
236,719
shares of Class A common stock pursuant to a separate agreement with an investor in the Series G-3 convertible preferred stock.
As of June 16, 2024, the Company’s redeemable convertible preferred stock had accrued $188.2 million of unpaid dividends, which were paid in 5,098,799 shares of Class A common stock at the closing of the IPO.
Outstanding shares of non-voting common stock were converted on a one-for-one basis into 5,069,477 shares of Class A common stock.
The restricted stock units (“RSUs”) granted to employees pursuant to the Company’s 2015 Plan are subject to two vesting conditions. The first is a time-based component. The second vesting condition is the occurrence of a liquidity event. The liquidity event condition related to these awards was satisfied upon the IPO and, as a result, the Company recognized $488.3 million of stock-based compensation expense
 
for the six months ended June 30, 2024
. In connection with the IPO, the Company settled an aggregate of 4,568,291 fully vested RSUs (the “IPO Settled RSUs”). To meet the related tax withholding requirements, the Company withheld 1,911,316 shares from the 4,563,164 shares of Class A common stock issuable upon settlement of the IPO Settled RSUs. Based on the public offering price of $37.00 per share, the tax withholding obligation was $70.8 million.
The Company issued 109,459
shares of Class A common stock upon the automatic net exercise of a warrant issued to Allen & Company LLC (“Allen”), as further described in Note 8.
In connection with the IPO, the Company amended and restated its certificate of incorporation (the “Restated Certificate”), under which authorized capital stock consists of
 
1,000,000,000
shares of Class A common stock,
5,500,000
shares of Class B common stock, and
20,000,000
shares of preferred stock.
 
2.
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Principles of Consolidation and Basis of Presentation
The condensed consolidated financial statements include the accounts of Tempus AI, Inc. and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The condensed consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (the “SEC”) regarding interim financial information and include the assets, liabilities, revenue and expenses of all wholly owned subsidiaries. Investments in unconsolidated entities in which the Company does not have a controlling financial interest, but has the ability to exercise significant influence, are accounted for under the equity method of accounting. Investments in unconsolidated entities in which the Company is not able to exercise significant influence are accounted for under the cost method of accounting. Certain information and disclosures normally included in the annual consolidated financial statements prepared in
 
9

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
accordance with GAAP have been omitted. Accordingly, the unaudited interim
condensed
consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes included in the Company’s final prospectus, dated June 13, 2024, filed with the SEC pursuant to Rule 424(b) under the Securities Act of 1933, as amended (the “Securities Act”), on June 17, 2024 (the “Prospectus”) in connection with the IPO. The unaudited interim
conde
nsed
consolidated financial statements have been prepared on the same basis as the audited consolidated financial statements and reflect, in management’s opinion, all the adjustments of a normal, recurring nature that are necessary for the fair statement of the Company’s financial position, results of operations, and cash flows for the interim periods, but are not necessarily indicative of the results expected for the full year or any other period.
In the opinion of the Company, the accompanying unaudited condensed consolidated financial statements contain all adjustments, consisting of only normal recurring adjustments, necessary for a fair statement of its financial position as of June 30, 2024 and its results of operations for the three and six months ended June 30, 2024 and 2023, and cash flows for the six months ended June 30, 2024 and 2023. The condensed consolidated balance sheet at December 31, 2023, was derived from audited annual financial statements but does not contain all of the footnote disclosures from the annual financial statements.
The Company believes that its existing cash and cash equivalents and marketable equity securities at June 30, 2024 will be sufficient to allow the Company to fund its current operating plan through at least a period of one year from the date of issuance. As the Company continues to incur losses, its transition to profitability is dependent upon a level of revenues adequate to support the Company’s cost structure. Future capital requirements will depend on many factors, including the timing and extent of spending on research and development activities and growth related expenditures.
Other than described below, there have been no changes to the Company’s significant accounting policies described in the “Notes to the Consolidated Financial Statements” included in the Company’s audited consolidated financial statements as of and for the year ended December 31, 2023 included in the Prospectus that have had a material impact on the Company’s consolidated financial statements and accompanying notes.
Reclassification
Certain prior year amounts have been reclassified for consistency with the current year presentation.
Emerging Growth Company
The Company is an “emerging growth company” as defined in Section 2(a) of the Securities Act, as modified by the Jumpstart Our Business Startups Act of 2012 (the “JOBS Act”), and it may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in its periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.
Further, Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Securities Exchange Act of 1934, as amended) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to
non-emerging
growth companies but any such election to opt out is irrevocable. The Company has elected not to opt out of such extended transition period which means that when a standard is issued or revised and it has different application dates for public or private companies, the Company, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of the Company’s
condensed
consolidated financial statements with another public company which is neither an emerging growth company nor an emerging growth company which has opted out of using the extended transition period difficult or impossible because of the potential differences in accounting standards used.
Use of Estimates
The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and classifications of assets and liabilities, revenue and expenses, and the related disclosures of contingent assets and liabilities in the condensed consolidated financial statements and accompanying notes. The most significant estimates are related to revenue, accounts receivable, stock-based compensation, operating lease liabilities, and the useful lives of property, equipment and intangible assets. Actual results could differ from those estimates.
 
10

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
Net Loss Per Share Attributable to Common Stockholders
Basic and diluted net loss per share attributable to common stockholders is presented in conformity
with
the
two-class
method required for participating securities. The Company considers all series of its redeemable convertible preferred stock to be participating securities. Prior to the IPO, under the
two-class
method, the net loss attributable to common stockholders was not allocated to the redeemable convertible preferred stock as the holders of its redeemable convertible preferred stock did not have a contractual obligation to share in the Company’s losses. Upon IPO, the Company’s redeemable convertible preferred stock converted to either Class A or Class B common stock and therefore will be included in allocation of net loss attributable to common stockholders as they will share in the Company’s losses. Net income is attributed to common stockholders and participating securities based on their participation rights. Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per share attributable to common stockholders adjusts basic earnings per share for the potentially dilutive impact of stock options and redeemable convertible preferred stock. As the Company has reported losses for all periods presented, all potentially dilutive securities are antidilutive and accordingly, basic net loss per share equals diluted net loss per share.
Deferred Offering Costs
Deferred offering costs consist primarily of accounting, legal, and other fees related to the IPO. The Company had
$
7.1
million of deferred offering costs as of December 31, 2023. Prior to the IPO, deferred offering costs were capitalized on the consolidated balance sheets. Upon the consummation of the IPO, $
12.3
 million of deferred offering costs were reclassified into additional
paid-in
capital as an offset against IPO proceeds.
Recently Issued Accounting Pronouncements Not Yet Adopted
In November 2023, the FASB issued ASU No. 2023-07, Segment Reporting (Topic 280), which provides enhanced disclosures about significant segment expenses. The standard also enhances interim disclosure requirements and provides new segment disclosure requirements for entities with a single reportable segment. The standard is effective for public companies for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. Retrospective adoption is required for all prior periods presented. Early adoption is permitted. The Company is currently evaluating the effect that this guidance will have on the consolidated financial statements and related disclosures.
In
December 2023, the FASB issued ASU
2023-09,
Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires public entities, on an annual basis, to provide disclosure of specific categories in the rate reconciliation, as well as disclosure of income taxes paid disaggregated by jurisdiction. ASU
2023-09
is effective for fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the effect that this guidance will have on the consolidated financial statements and related disclosures.


11

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
3.
REVENUE RECOGNITION
The Company derives revenue from selling lab services (“Genomics”) to physicians, academic research institutions, and other parties. The Company also derives revenue from the commercialization of data generated in the lab (“Data and services”) through the licensing of
de-identified
datasets to third parties and by providing clinical trial support, such as matching patients to clinical trials enrolled in its clinical trial network, and related services. The majority of the Company’s revenue is generated in North America.
The Company accounts for revenue in accordance with Financial Accounting Standards Board (“FASB”) ASC 606
Revenue from Contracts with Customers
(“ASC 606”). The Company commences revenue recognition when control of these products is transferred to customers in an amount that reflects the consideration the Company expects to be entitled to in exchange for such products. This principle is achieved by applying the five-step approach: (i) the Company accounts for a contract when it has approval and commitment from both parties, (ii) the rights of the parties are identified, (iii) payment terms are identified, (iv) the contract has commercial substance and (v) collectability of consideration is probable. Revenues and any contract assets are not recognized until such time that the required conditions are met.
Disaggregation of Revenue
The Company provides disaggregation of revenue based on Genomics and Data and services on the condensed consolidated statements of operations and comprehensive loss, as it believes these best depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
Genomics
The Company generally recognizes revenue for its Genomics product offering when it has met its performance obligation relating to an order. The Company has determined its sole performance obligation to be the delivery of the testing results to the ordering party. The Company receives payments from Medicare, Medicaid, and commercial insurance for clinical orders and directly from research institutions, pharmaceutical companies or other third parties for direct bill orders. The Company recognized Genomics revenue of $112.3 million and $91.9 million for the three months ended June 30, 2024 and 2023, respectively. The Company recognized Genomics revenue of $214.9 million and $174.0 million for the six months ended June 30, 2024 and 2023, respectively.
For clinical orders from Medicare, Medicaid, and commercial insurance, the Company determines transaction price by reducing the standard charge by the estimated effects of any variable consideration, such as contractual allowance and implicit price concessions. The Company estimates the contractual allowances and implicit price concessions based on historical collections in relation to established rates, as well as known current or anticipated reimbursement trends not reflected in the historical data. Estimates are inclusive of the consideration to which the Company will be entitled at an amount for which it is probable that a reversal of cumulative consideration will not occur. The Company monitors the estimated amount to be collected at each reporting period based on actual cash collections in order to assess whether a revision to the estimate is required. Payment is typically due after the claim has been processed by the payer, generally
30-120
days from date of service. While management believes that the estimates are accurate, actual results could differ and the potential impact on the financial statements could be significant. The Company recognized revenue for clinical orders
of $101.7 million and $84.4 million for the three months ended June 30, 2024 and 2023, respectively. The Company recognized revenue for clinical orders of $195.1 million and $156.9 million for the six months ended June 30, 2024 and 2023, respectively.
For direct bill orders from research institutions, pharmaceutical companies, or other third parties, the Company determines the transaction prices based on established contractual rates with the customer, net of any applicable discounts. Payment is typically due between 30 and 60 days following the date of invoice. The Company recognized Genomics revenue for direct bill orders of $10.6 million and $7.5 million for the three months ended June 30, 2024 and 2023, respectively
 and
 $19.8 million and $17.1 million for the six months ended June 30, 2024 and 2023, respectively.
 
12

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
Data and services
Data and services revenue primarily represents data licensing and clinical trial services that the Company provides to pharmaceutical and biotechnology companies. The Company’s arrangements with these customers often have terms that span multiple years. However, these contracts generally also include customer
opt-in
or early termination clauses after twelve months without contractual penalty. The customer’s option to renew is generally not viewed as a material right, and as a result, the Company’s contract period for these agreements is generally considered less than one year. The Company determines the transaction price based on established contractual rates with the customer, net of any applicable discounts. The Company recognizes revenue for its Data and services product offering when it has met its performance obligation under the terms of the agreement with the customer. The Company’s two product offerings are as follows:
Insights
The Company’s Insights product consists primarily of licensing and analysis of
de-identified
records. Each Insights contract is unique and may include multiple promises, including the delivery of licensed
de-identified
records, including refreshes, analytical services or access to the Company’s enhanced Lens application. The Company evaluates each contract to determine which performance obligations are capable of being distinct and separately identifiable from other promises in the contract and, therefore, represent distinct performance obligations. The actual timing of data deliveries can be based on a variety of factors, including, but not limited to, the customer’s requirement and/or the Company’s technological, operational, and human capital capacity; in addition, management assesses relevant contractual terms in contracts with customers and applies significant judgment in identifying and accounting for all terms and conditions in certain contracts. The transaction price is allocated to the distinct performance obligations and revenue is recognized once the performance obligation has been fulfilled. The standalone selling prices are based on the Company’s normal pricing practices when sold separately with consideration of market conditions and other factors, including customer demographics.
The Company has determined that the delivery of
de-identified
records and, when applicable, analytical services, and access to its enhanced Lens application are separate and distinct performance obligations. The primary Insights contract types are as follows:
 
   
Data licensing on a
one-time
or limited duration basis
– Customer licenses a specific dataset of records, and the Company accounts for individual licensed data records as a right to use license. Revenue is typically recognized upon delivery of the data to the customer, as the Company’s obligations for an individual record is complete once the data has been delivered, and the customer is able to benefit from the provision of data as it is received.
 
   
Multi-year data subscriptions
– Customer licenses an interchangeable maximum number of
de-identified
records, and the Company accounts for the service as a right to access license and one performance obligation. Revenue is recognized as access to the dataset is provided, ratably over-time, with the measure of progress time-based.
 
   
Analytical services and other services
– Services typically involve data analysis and research performed on behalf of the customer by the Company. The resulting delivery of data, or a report addressing a series of questions and analytical results, is considered a single performance obligation. Revenue is generally recognized upon the delivery of these services, as defined by the contract.
 
   
Enhanced Lens application subscription services
– Customer licenses access to the Company’s enhanced Lens application under a
software-as-a-service
model. Customers do not have the right to take possession of the Lens platform application, and the online software product is fully functional once a customer has access. Lens subscription revenues are recognized ratably over the contract terms beginning on the date the Company’s service is made available to the customer. For the periods presented, revenue from Lens subscription services are not material.
 
13

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
The Company recognized revenue from Insights products of $40.7 million and $29.1 million for the three months ended June 30, 2024 and 2023, respectivel
y
and
$72.0 million and $51.9 million for the six months ended June 30, 2024 and 2023, respectively.
Trials
The Company’s Trials product includes TIME clinical trial matching services and other clinical trial services.
TIME consists primarily of matching patients to clinical trial sponsors of a potential match. To the extent the contract requires, the Company may also assist in opening the clinical trial site and enrolling the patient in the clinical trial. The Company has determined that, depending on the type of agreement, the performance obligation of these contracts is the delivery of a notification or the enrollment of a patient in a clinical trial. As such, revenue is recognized upon one of the following: delivery of a notification to the physician alerting them to a clinical trial match, or once a patient is enrolled in a trial. Concurrently, the customer, which is the clinical trial sponsor, also receives notification from the Company to establish the performance obligations delivered or fulfilled for the billing period.
In addition to TIME, the Company provides other clinical trial services conducting or supporting studies. Tempus Compass LLC, a subsidiary of the Company, is a contract research organization, or CRO, which manages and executes early and late-stage clinical trials, primarily in oncology. Contracts for clinical trial services can take the form of
fee-for-service
or fixed-price contracts.
Fee-for-service
contracts are typically priced based on time and materials, and revenue is recognized based on hours and materials used as the services are provided. Fixed-price contracts generally represent a single performance obligation and are recognized over-time using a cost-based input method. Progress on the performance obligation is measured by the proportion of actual costs incurred to the total costs expected to complete the contract. This cost-based method of revenue recognition requires the Company to make estimates of costs to complete its projects on an ongoing basis. Contract costs principally include direct labor and reimbursable
out-of-pocket
costs.
The Company recognized revenue from Trials products of $10.5 million and $10.6 million for the three months ended June 30, 2024 and 2023, respectively
 
and
 $21.8 million and $20.9 million for the six months ended June 30, 2024 and 2023, respectively.
For Insights and Trials arrangements, pricing is fixed and the Company may be compensated through a combination of an upfront payment and performance-based,
non-refundable
payments due upon completion of the stated performance obligation(s). Payment is generally due 60 to 90 days after the date of service. The Company has no significant obligations for refunds, warranties, or similar obligations for Data and services product offerings. The Company has elected the practical expedient, which allows the Company to not disclose remaining performance obligations for contracts with original terms of twelve months or less. Cancelable contracted revenue is not considered a remaining performance obligation. The Company recognized Data and other revenue from pharmaceutical companies,
non-for-profits,
and researchers of $53.6 million and $40.5 million for the three months ended June 30, 2024 and 2023, respectively
 
and $96.9 million and $74.1 million for the six months ended June 30, 2024 and 2023, respectively.
Multi-year contract performance obligations
The Company has limited multi-year contracts that do not contain early termination or customer
opt-in
clauses. These contracts contained defined, noncancelable performance obligations that will be fulfilled in future years. The Company’s remaining performance obligations related to multi-year contracts was
$
197.3 million as of June 30, 2024, of which the Company expects to recognize approximately 42
%
 as revenue over the next year, and the remaining 34%, 19%, and 5
%
 of its
remaining performance obligations as revenue in years two, three, and four, respectively.
 
14

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
 
Contract Assets
Timing of revenue recognition may differ from the timing of invoicing to customers. Certain performance obligations may require payment before delivery of the service to the customer. The Company recognizes contract assets when the Company has an unconditional right to payment, and when revenues earned on a contract exceeds the billings. Contract assets are presented under accounts receivable, net. Accounts receivable as of June 30, 2024 and December 31, 2023 included contract assets
of $9.3 million and $2.4 million, respectively.
During the fourth quarter of 2021, and in conjunction with the signing of a November 2021 Master Services Agreement (“the MSA”) with customer AstraZeneca AB (“AstraZeneca”), the Company recognized a contract asset for consideration payable concurrent with the issuance of the common stock warrant in accordance with ASC 606. The contract asset was initially measured equal to the initial fair value of the warrant liability based on the authoritative guidance under FASB ASC 718
Compensation—Stock Compensation
. As revenue is recognized over the period of the contractual commitment of the MSA, the associated contract asset amortization is recorded as reduction of revenue. At each reporting period, the short-term portion of the warrant asset is adjusted based on the financial commitment and reclassified to Prepaid expenses and other current assets.
The following summarizes the warrant contract asset presentation as of June 30, 2024 and December 31, 2023 (in thousands):

 
  
June 30, 2024
 
  
December 31, 2023
 
Prepaid expenses and other current assets
   $  4,843      $ 4,843  
Warrant contract asset, less current portion
     19,077        21,499